Our model-predicted survivals are influenced by the standard time-fixed variables of age, race, stage, hormone and Her2 status, tumor grade, as outlined in countless prior studies referenced above, as well as by the impact of treatments, treatment-associated adverse events, age and comorbidity progression with treatment, which collectively have positive and negative impacts on the relationship of the model-based survival and population-averaged survival. This evidence concerns the gene ERBB2 and neoplasm.